Active Ingredient(s): Pemigatinib
FDA Approved: * April 17, 2020
Pharm Company: * INCYTE CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Pemazyre Overview

Pemigatinib, sold under the brand name Pemazyre, is a medication for the treatment of bile duct cancer (cholangiocarcinoma).[1][2][3][4] Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.[3] Pemigatinib belongs to a group of medicines called protein kinase inhibitors.[5] It works by blocking enzymes known as protein kinases, particularly those that are pa...

Read more Pemazyre Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Pemazyre Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 13.5mg, 4.5mg, 9mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Pemazyre: (3 results)

Sorted by National Drug Code
  • 50881-026 Pemazyre 4.5 mg Oral Tablet by Incyte Corporation
  • 50881-027 Pemazyre 9 mg Oral Tablet by Incyte Corporation
  • 50881-028 Pemazyre 13.5 mg Oral Tablet by Incyte Corporation

Other drugs which contain Pemigatinib or a similar ingredient: (1 result)